Opinion|Videos|April 28, 2025
The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies
Experts discuss how lipoprotein(a) (Lp[a]) testing, even without targeted Lp(a)-lowering therapies, can enhance overall cardiovascular risk assessment and potentially influence the management of other risk factors.
Advertisement
Video content above is prompted by the following:
- Previously, I mentioned the benefits of Lp(a) testing, even in the absence of targeted Lp(a)-lowering therapies. Let’s explore that further. How might Lp(a) testing improve overall cardiovascular risk assessment?
- How, if at all, might Lp(a) measurement influence the management of other risk factors?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
2
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
3
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
4
Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk
5